4.5 Article

Localized transmeningeal muscimol prevents neocortical seizures in rats and nonhuman primates: Therapeutic implications

Journal

EPILEPSIA
Volume 50, Issue 4, Pages 678-693

Publisher

WILEY
DOI: 10.1111/j.1528-1167.2008.01914.x

Keywords

Muscimol; Acetylcholine; Dura mater; Pia mater; Neocortical seizures

Funding

  1. NIH/SBIR [5 R44 MH080693-03]

Ask authors/readers for more resources

To determine whether muscimol delivered epidurally or into the subarachnoid space can prevent and/or terminate acetylcholine (Ach)-induced focal neocortical seizures at concentrations not affecting behavior and background electroencephalography (EEG) activity. Rats (n = 12) and squirrel monkeys (n = 3) were chronically implanted with an epidural or subarachnoid drug delivery device, respectively, over the right frontal/parietal cortex, with adjacent EEG electrodes. Recordings were performed in behaving rats and chaired monkeys. Via the implants, either a control solution (artificial cerebrospinal fluid, ACSF) or muscimol (0.25-12.5 mm) was delivered locally as a pretreatment, followed by the similar delivery of a seizure-inducing concentration of Ach. In five additional rats, the quantities of food-pellets consumed during epidural ACSF and muscimol (2.5 mm) exposures were measured. In a last group of four rats, muscimol (0.8-2.5 mm) was delivered epidurally during the ongoing, Ach-induced EEG seizure. In contrast to ACSF pretreatments, epidural muscimol pretreatment in rats completely prevented the seizures at and above 2.5 mm. In the monkeys, subarachnoid muscimol pretreatments at 2.5 mm completely prevented the focal-seizure-inducing effect of Ach, whereas similar deliveries of ACSF did not affect the seizures. Furthermore, 2.5 mm epidural muscimol left the eating behavior of rats intact and caused only slight changes in the EEG power spectra. Finally, muscimol delivery during Ach-induced EEG seizures terminated the seizure activity within 1-3 min. The results of this study suggest that muscimol is a viable candidate for the transmeningeal pharmacotherapy of intractable focal epilepsy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Vascular risk factors as predictors of epilepsy in older age: The Framingham Heart Study

Maria Stefanidou, Jayandra J. Himali, Orrin Devinsky, Jose R. Romero, Mohammad Arfan Ikram, Alexa S. Beiser, Sudha Seshadri, Daniel Friedman

Summary: The study found that hypertension is a risk factor for predicting late-onset epilepsy, with nearly 2-fold increased risk even after adjustment for previous and interim stroke.

EPILEPSIA (2022)

Article Clinical Neurology

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6

Joyce Y. Wu, Hannah R. Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Colin M. Roberts, Rocio Sanchez-Carpintero, Daniel Checketts, Farhad Sahebkar

Summary: By conducting a post hoc analysis of GWPCARE6 trial, the onset of CBD treatment effect was found to occur within 6-10 days. AEs lasted longer for CBD patients, but most patients experienced resolution of common AEs during the 16-week trial.

EPILEPSIA (2022)

Article Clinical Neurology

Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis

Joseph Sullivan, Nicola Specchio, Orrin Devinsky, Stephane Auvin, M. Scott Perry, Adam Strzelczyk, Antonio Gil-Nagel, David Dai, Bradley S. Galer, Arnold R. Gammaitoni

Summary: The study demonstrates that adjunctive use of fenfluramine can significantly reduce day-to-day seizure burden in patients with DS, providing prolonged periods of convulsive seizure-free days, which may help reduce the physical and emotional disease toll while improving health-related quality of life for patients and caregivers.

EPILEPSIA (2022)

Editorial Material Clinical Neurology

Epilepsy Mortality The Unseen and Unknown

Orrin Devinsky

NEUROLOGY (2022)

Article Multidisciplinary Sciences

Imagined speech can be decoded from low- and cross-frequency intracranial EEG features

Timothee Proix, Jaime Delgado Saa, Andy Christen, Stephanie Martin, Brian N. Pasley, Robert T. Knight, Xing Tian, David Poeppel, Werner K. Doyle, Orrin Devinsky, Luc H. Arnal, Pierre Megevand, Anne-Lise Giraud

Summary: Researchers extracted consistent and specific neural features from patients performing speech production tasks and found that low-frequency power and cross-frequency dynamics play a key role in decoding imagined speech.

NATURE COMMUNICATIONS (2022)

Article Biochemistry & Molecular Biology

A cortical network processes auditory error signals during human speech production to maintain fluency

Muge Ozker, Werner Doyle, Orrin Devinsky, Adeen Flinker

Summary: Hearing one's own voice is crucial for fluent speech production and can help detect and correct vocalization errors in real time. Research has found that both the auditory cortex and the dorsal precentral gyrus play important roles in processing auditory error signals during speech production.

PLOS BIOLOGY (2022)

Article Psychology, Biological

Multiscale temporal integration organizes hierarchical computation in human auditory cortex

Sam Norman-Haignere, Laura K. Long, Orrin Devinsky, Werner Doyle, Ifeoma Irobunda, Edward M. Merricks, Neil A. Feldstein, Guy M. McKhann, Catherine A. Schevon, Adeen Flinker, Nima Mesgarani

Summary: The human brain integrates information across multiple timescales to derive meaning from sound. Our study reveals that the auditory cortex hierarchically integrates across diverse timescales ranging from 50 to 400 ms, and different neural populations with short and long integration windows exhibit distinct functional properties.

NATURE HUMAN BEHAVIOUR (2022)

Article Clinical Neurology

Serotonin transporter in the temporal lobe, hippocampus and amygdala in SUDEP

Smriti Patodia, Alyma Somani, Joan Liu, Alice Cattaneo, Beatrice Paradiso, Maria Garcia, Muhammad Othman, Beate Diehl, Orrin Devinsky, James D. Mills, Jackie Foong, Maria Thom

Summary: Multiple lines of evidence suggest a link between deficient serotonin function and SUDEP, with chronic treatment using serotonin reuptake inhibitors shown to reduce the risk factors associated with SUDEP. Decreased medullary serotonergic neurons, which regulate respiration in response to hypercapnia, have been found in post-mortem SUDEP cases. Additionally, the high innervation of serotonergic neurons in the amygdala and hippocampus, regions involved in seizure-related respiratory dysregulation, further supports the potential involvement of altered serotonergic networks in SUDEP.

BRAIN PATHOLOGY (2022)

Article Clinical Neurology

Long- term efficacy and safety of cannabidiol in patients with treatment- resistant epilepsies: Four- year results from the expanded access program

Jerzy P. P. Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D. D. Park, Pilar Pichon Zentil, Anup D. D. Patel, Elizabeth A. A. Thiele, Robert T. T. Wechsler, Daniel Checketts, Farhad Sahebkar

Summary: The CBD expanded access program initiated in 2014 provided additional CBD treatment for patients with treatment-resistant epilepsies. The study showed that CBD treatment was effective in reducing seizure frequency and had an acceptable safety profile for long-term use in patients with treatment-resistant epilepsies.

EPILEPSIA (2023)

Article Clinical Neurology

Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program

Robert J. Flamini, Anne M. Comi, E. Martina Bebin, Michael G. Chez, Gary Clark, Orrin Devinsky, Shaun A. Hussain, Paul D. Lyons, Anup D. Patel, Jillian L. Rosengard, Farhad Sahebkar, Eric Segal, Laurie Seltzer, Jerzy P. Szaflarski, Arie Weinstock

Summary: The CBD Expanded Access Program provided CBD treatment to patients with treatment-resistant epilepsy and showed a significant reduction in seizure frequency. CBD was well tolerated and effective in treating both convulsive and nonconvulsive seizure types. Controlled trials are needed to further confirm these findings.

EPILEPSIA (2023)

Editorial Material Clinical Neurology

Failure to use new breakthrough treatments for epilepsy

Pavel Klein, Gregory L. Krauss, Bernhard J. Steinhoff, Orrin Devinsky, Michael R. Sperling

Summary: Despite the approval of numerous antiseizure medications (ASMs), a significant number of epilepsy patients still experience seizures. Two new ASMs, cenobamate and fenfluramine, have shown improved efficacy in reducing seizures with sustained results. However, these medications are underutilized, likely due to limited knowledge, access restrictions, and insufficient post-launch information about their efficacy and safety. Addressing these issues can improve seizure control and ultimately reduce morbidity and mortality in epilepsy patients.

EPILEPSIA (2023)

Article Clinical Neurology

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial

Joseph Sullivan, Lieven Lagae, J. Helen Cross, Orrin Devinsky, Renzo G. Guerrini, Kelly Knupp, Linda Laux, Marina Nikanorova, Tilman Polster, Dinesh Talwar, Berten Ceulemans, Rima M. Nabbout, Gail S. Farfel, Bradley R. Galer, Arnold Gammaitoni, Michael Lock, Anupam E. Agarwal, Ingrid Scheffer, FAiRE DS Study Grp

Summary: This study examined the safety and effectiveness of fenfluramine in treating convulsive seizures in patients with Dravet syndrome. The results showed that patients treated with fenfluramine had lower seizure frequency and longer interval between seizures compared to the placebo group. Common side effects of fenfluramine were observed, but no evidence of severe cardiac or vascular issues was found.

EPILEPSIA (2023)

Review Clinical Neurology

Are brief febrile seizures benign? A systematic review and narrative synthesis

Laura Gould, Victoria Delavale, Caitlin Plovnick, Thomas Wisniewski, Orrin Devinsky

Summary: Febrile seizures are associated with an increased risk of epilepsy and rare cases of sudden unexplained death. Mortality rates varied in different studies, with some reporting no deaths and others identifying a significant percentage of deaths associated with febrile seizures. Minor hippocampal histopathological anomalies were common in sudden deaths with or without a history of febrile seizures. Most electroencephalography (EEG) studies were normal, and neuroimaging studies suggested increased right hippocampal volumes. Longer-term prospective studies are needed to fully understand the outcomes of simple or brief complex febrile seizures.

EPILEPSIA (2023)

Article Multidisciplinary Sciences

Closed-loop brain stimulation augments fear extinction in male rats

Rodrigo Ordonez Sierra, Lizeth Katherine Pedraza, Livia Barcsai, Andrea Pejin, Qun Li, Gabor Kozak, Yuichi Takeuchi, Anett J. Nagy, Magor L. Lorincz, Orrin Devinsky, Gyoergy Buzsaki, Antal Berenyi

Summary: Dysregulated fear reactions can be caused by maladaptive processing of trauma-related memories. By manipulating hippocampal SWRs and cortical oscillations, fear extinction can be enhanced in male rats. The modified fear memories become resistant to recall and do not spontaneously reemerge. This effect is mediated by D2 receptor signaling-induced synaptic remodeling in the basolateral amygdala. These findings demonstrate the potential of neuromodulation in augmenting extinction learning and provide a new avenue for anxiety disorder treatments.

NATURE COMMUNICATIONS (2023)

Article Clinical Neurology

Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up

Heather E. Olson, Sam Amin, Nadia Bahi-Buisson, Orrin Devinsky, Eric D. Marsh, Elia Pestana-Knight, Rajsekar R. Rajaraman, Alex A. Aimetti, Eva Rybak, Fanhui Kong, Ian Miller, Joseph Hulihan, Scott Demarest

Summary: This study reports the 2-year safety and clinical outcomes of ganaxolone treatment in patients with CDD. The results show that ganaxolone significantly reduces major motor seizure frequency and maintains its efficacy and safety over the long term.

EPILEPSIA (2023)

No Data Available